参考文献/References:
[1] Cuperus FJ,Halilbasic E,Trauner M.Fibrate treatment for primary biliary cirrhosis[J].Curr Opin Gastroenterol,2014,30(3):279-286.
[2] European Association for the Study of the Liver.EASL clinical practiceguidelines:management of cholestatic liver diseases[J].J Hepatol,2009,51(2):237-267.
[3] 姚光弼.临床肝脏病学[M].2版.上海:上海科学技术出版社,2011:556-560.
Yao GB.Introdution clinical liver epidemiology[M].Second Edition.Shanghai:Shanghai Scientific and Technical Publishers,2011:556-560.
[4] 何丽芬,赖伊杰,赖力英,等.原发性胆汁性肝硬化的临床特点[J].中南大学学报(医学版),2015,40(12):1333-1339.
He LF,Lai YJ,Lai LY,et al.Clinical features of patients with primary biliary cirrhosis[J].Journal of Central South University(Medical Edition),2015,40(12):1333-1339.
[5] 秦 雯,余 俊.原发性胆汁性肝硬化自身抗体检测结果分析及临床应用[J].检验医学与临床,2015,12(4):484-485,488.
Qin W,Yu J.Results analysis and clinical application of auto-antibodies detection in primary biliary cirrhosis[J].Laboratory Medicine and Clinic,2015,12(4):484-485,488.
[6] 李秀娥,王 禺,赵 雅.自身免疫性肝病相关自身抗体谱的检测在原发性胆汁性肝硬化患者中的临床应用[J].现代检验医学杂志,2012,27(4):65-67.
Li XE,Wang Y,Zhao Y.Clinical significance of detection autoimmuneliver disease related autoantibody profiles in patients with primary biliary cirrhosis[J].Journal of Modern Laboratory Medicine,2012,27(4):65-67.
[7] 张 丽,白石山.原发性胆汁性肝硬化患者血清AMA-M2及其靶抗原检测的阳性率对比[J].内蒙古医学杂志,2013,45(5):529-533.
Zhang L,Bai SS.Contrast of AMA-M2 and its target antigen detection sensitivity in patient's serum with prinary biliary cirrhosis[J].Inner Mongolia Medical Journal,2013,45(5):529-533.
[8] Bruan S,Berg C,Buck S,et al.Catalytic domain of PDC-E2 contains epitopes recognized by antimitochondrial antibodies in primary biliary cirrhosis[J].World J Gastroenterol,2010,16(8):973-981.
[9] Cuperus FJ,Halilbasic E,Trauner M.Fibrate treatment for primary biliary cirrhosis[J].Curroopin Gastroenterol,2014,30(3):279-286.
[10] 李凤惠,吕洪敏,向慧玲,等.血清抗GP210抗体对PBC患者的诊断价值[J].天津医科大学学报,2011,17(4):549-552.
Li FH,L(¨overu)HM,Xiang HL,et al.Serum anti-gp210 antibody of PBCpatients[J].Journal of Tianjin Medical University,2011,17(4):549-552.
[11] 唐映梅,包维民,尤丽英,等.原发性胆汁性肝硬化患者血清抗GP210和抗SP100检测的临床意义[J].实用肝脏病杂志,2011,14(2):132-134.
Tang YM,Bao WM,You LY,et al.Clinical significance of serum anti-SP100and anti-GP210 detection in diagnosis of patients with primary biliary cirrhosis[J].Journal of Clinical Hepatology,2011,14(2):132-134.
[12] 邵幼林,张锁才,吴剑明,等.抗Gp210阳性原发性胆汁性肝硬化患者临床特征[J].海南医学杂志,2016,27(5):766-769.
Shao YL,Zhang SC,Wu JM,et al.Clinical characteristics of patients ofprimary biliary cirrhosis with anti Gp210 positive[J].Hainan Medical Journal,2016,27(5):766-769.
[13] 李 虎,陈 燕,张 蕾,等.原发性胆汁性肝硬化患者外周血Th9细胞表达增高及其临床意义[J].现代检验医学杂志,2016,31(3):16-18,21.
Li H,Chen Y,Zhang L,et al.Expression of Th9 cells from peripheral blood of primary biliary cirrhosis patients and its clinical significance[J].Journal of Modern Laboratory Medicine,2016,31(3):16-18,21.